POCone-UBiT-IR300 Pediatric Comparison Study
- Conditions
- Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
- First Posted Date
- 2012-06-19
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 99
- Registration Number
- NCT01623154
- Locations
- ๐บ๐ธ
Miami Pediatric Gastroenterology, Miami, Florida, United States
๐บ๐ธUniversity of Texas School of Public Health, El Paso, Texas, United States
๐บ๐ธBaylor College of Medicine, Houston, Texas, United States
Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia
- Conditions
- Euvolemic HyponatremiaHypervolemic Hyponatremia
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2015-05-15
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 5028
- Registration Number
- NCT01240668
- Locations
- ๐บ๐ธ
North America Research Institute, Azusa, California, United States
๐บ๐ธChrishard Medical Group, Inglewood, California, United States
๐บ๐ธUCLA, Los Angeles, California, United States
Study for the Treatment of Crohn's Disease With Adacolumn
- Conditions
- Crohn's Disease
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2009-04-07
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 235
- Registration Number
- NCT00162942
- Locations
- ๐บ๐ธ
Mayo Clinic Scottsdale, Phoenix, Arizona, United States
๐บ๐ธCapitol Gastroenterology Consultants Medical Group, Roseville, California, United States
๐บ๐ธUCSF Mount Zion Medical Center, San Francisco, California, United States
Study for the Treatment of Ulcerative Colitis With Adacolumn
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2005-01-25
- Last Posted Date
- 2008-09-08
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 168
- Registration Number
- NCT00102193
- Locations
- ๐บ๐ธ
Mayo Clinic Scottsdale, Phoenix, Arizona, United States
๐บ๐ธProvidence Clinical Research, Burbank, California, United States
๐บ๐ธUniversity of California, San Francisco, San Francisco, California, United States
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
- Conditions
- Raynaud's Disease
- First Posted Date
- 2002-11-11
- Last Posted Date
- 2005-07-19
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 75
- Registration Number
- NCT00048763
- Locations
- ๐บ๐ธ
Advanced Medical Clinical Therapeutics, Anchorage, Alaska, United States
๐บ๐ธAdvanced Medical Research Institute, Fresno, California, United States
๐บ๐ธMadera Family Medical Group, Madera, California, United States
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
- Conditions
- Raynaud's Disease
- First Posted Date
- 2002-11-11
- Last Posted Date
- 2005-07-19
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 75
- Registration Number
- NCT00048776
- Locations
- ๐บ๐ธ
Advanced Medical Clinical Therapeutics, Anchorage, Alaska, United States
๐บ๐ธAdvanced Medical Research Institute, Fresno, California, United States
๐บ๐ธMadera Family Medical Group, Madera, California, United States
A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
- Conditions
- Sarcoma, KaposiHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT00002131
- Locations
- ๐บ๐ธ
UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธNorthwestern Univ Med School, Chicago, Illinois, United States
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Otsuka America Pharmaceutical
- Registration Number
- NCT00002130
- Locations
- ๐บ๐ธ
UCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธAIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 36
- Registration Number
- NCT00002129
- Locations
- ๐บ๐ธ
UCLA School of Medicine, Los Angeles, California, United States
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Otsuka America Pharmaceutical
- Target Recruit Count
- 56
- Registration Number
- NCT00002337
- Locations
- ๐บ๐ธ
AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States